GlassScriptPhysician profile
Adil Pervaiz
NPI 1174937940
$2,403.29
in general payments reported to CMS, 2019-2025
22 companies · $473 in 2025
The $473 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.05 · 2020: $109 · 2021: $270 · 2022: $801 · 2023: $319 · 2024: $407 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,199.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $418.63 | 2022-2025 | |
| Abiomed | $306.04 | 2022-2024 | Impella |
| Boston Scientific Corporation | $233.26 | 2022 | |
| Medtronic, INC. | $222.69 | 2021-2023 | Cg Future |
| Abbott Laboratories | $192.76 | 2022 | |
| Amgen INC. | $154.73 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.40 | 2023-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $95.68 | 2020-2024 | |
| Novo Nordisk INC | $91.68 | 2023-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.33 | 2020-2024 | Jardiance |
| Pfizer INC. | $85.06 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $79.02 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $61.23 | 2023-2025 | Camzyos, Eliquis |
| Shockwave Medical, INC | $49.32 | 2021 | |
| Irhythm Technologies, INC. | $43.97 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $37.59 | 2023 | |
| Merck Sharp & Dohme LLC | $31.96 | 2023 | Verquvo |
| Acist Medical Systems, INC. | $30.07 | 2023 | |
| Kestra Medical Technology Services, INC. | $29.45 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $15.14 | 2024 | Arcalyst |
| Astellas Pharma US INC | $15.10 | 2021 | |
| Cashflow Solutions, LLC | $12.18 | 2024 | Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adil Pervaiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.